Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
RESEARCH TOOLSreports
Holding SUPN?
Track your performance easily
SUPN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.53 - $39.37
Previous Close$36.61
Volume425.68K
Average Volume (3M)372.34K
Market Cap
$2.02B
Enterprise Value$1.65B
Total Cash (Recent Filing)$403.21M
Total Debt (Recent Filing)$28.93M
Price to Earnings (P/E)34.3
Beta0.88
Next Earnings
Mar 04, 2025EPS Estimate
$0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.07
Shares Outstanding55,219,273
10 Day Avg. Volume569,116
30 Day Avg. Volume372,340
Standard Deviation0.10
R-Squared0.19
Alpha-0.00182
Financial Highlights & Ratios
Price to Book (P/B)2.07
Price to Sales (P/S)3.10
Price to Cash Flow (P/CF)9.40
P/FCF Ratio9.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.57
Enterprise Value/Gross Profit3.15
Enterprise Value/Ebitda10.00
Forecast
1Y Price Target
$39.25Price Target Upside3.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Supernus Pharmaceuticals News
PremiumCompany Announcements
Supernus Pharmaceuticals Reports Strong Q3 2024 Results
PremiumPre-Earnings
Is SUPN a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Market PotentialQelbree is expected to capture a significant share of the ADHD market, potentially becoming a $750MM+ product.
Regulatory ProgressThe FDA's approval of ABBV's Parkinson's pump could have a positive effect on SPN-830's path to approval, partially de-risking it.
Sales PerformanceQelbree sales have exceeded expectations, indicating solid demand and a positive market reception.
Bears Say
Long-term GrowthAnalysts are rethinking assumptions regarding the longer-term sales/volume growth trajectory of Qelbree.
Market CompetitionOxtellar XR has lost a 34% weekly TRx share to Apotex, a generic competitor.
Sales GrowthThe sizable uptick in prescription (Rx) growth for Qelbree that was expected amid the back-to-school season has not quite come to pass.
---
Ownership Overview
4.24% Insiders
32.22% Mutual Funds
10.18% Other Institutional Investors
21.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SUPN FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $25.53 and its highest was $39.37 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Currently, no data Available
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 107 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on Nov 04, 2024. The company reported $1.168 earnings per share for the quarter, beating the consensus estimate of $0.443 by $0.725.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is $0.5.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 55,219,273 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $1.168 in its last earnings report, beating expectations of $0.443. Following the earnings report the stock price went up 0.115%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Among the largest hedge funds holding Supernus Pharmaceuticals’s share is Third Avenue Management LLC. It holds Supernus Pharmaceuticals’s shares valued at 5M.
---
Supernus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.25 (3.75% Upside)
$39.25 (3.75% Upside)
Blogger Sentiment
Bullish
SUPN Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.37%
12-Months-Change
Fundamentals
Return on Equity
6.22%
Trailing 12-Months
Asset Growth
4.48%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
---
SUPN Earnings Call
Q3 2024
0:00 / 0:00
---
SUPN Stock 12 Month Forecast
Average Price Target
$39.25
▲(3.75% Upside)
Technical Analysis
Amneal Pharmaceuticals
―
Eagle Pharmaceuticals
―
Ironwood Pharma
―
Pacira Pharmaceuticals
―
Best Analysts Covering SUPN
1 Year
---